Cefditoren pivoxil: A review of its use in the treatment of bacterial infections

Drugs

Volumn 64, Issue 22, 2004, Pages 2597-2618

  Wellington, Keri ^a   Curran, Monique P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM DERIVATIVE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; BETA LACTAMASE; CARNITINE; CEFDITOREN; CEFDITOREN PIVOXIL; CEFIXIME; CEFOTAXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MAGNESIUM DERIVATIVE; METICILLIN; ORAL CONTRACEPTIVE AGENT; PENICILLIN BINDING PROTEIN; PENICILLIN G; PENICILLIN V; PROTON PUMP INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; CARNITINE DEFICIENCY; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG STABILITY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HEMATURIA; HUMAN; MAXILLA SINUSITIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NONHUMAN; PHARYNGITIS; PSEUDOMEMBRANOUS COLITIS; REVIEW; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TONSILLITIS; VAGINA CANDIDIASIS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; CLINICAL TRIALS; DRUG RESISTANCE, BACTERIAL; DRUG STABILITY; HUMANS; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; MORAXELLA CATARRHALIS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 9944248106     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464220-00009     Document Type: Review

References (72)

1. Kuti JL, Quintiliani R. Cefditoren pivoxil: a novel broad-spectrum oral cephalosporin. Formulary 2001; 36: 265-8 and 271-275
2. Purdue Pharmaceutical Products L.P. Package insert: Spectracef® tablets (cefditoren pivoxil) [online]. Available from URL: http://www.pharma. com/PI/Prescription/spectracef.pdf [Accessed 2004 Aug 23]
3. Tedec-Meiji Farma S.A. Summary of product characteristics: Spectracef® film-coated tablets. Madrid: Tedec-Meiji Farma S.A., 2004
4. Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs 2002; 62 (2): 319-36; discussion 337-8
5. Kelly LM, Jacobs MR, Appelbaum PC. Comparison of agar dilution, microdilution, E-test, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae. J Clin Microbiol 1999; 37 (10): 3296-9
6. Johnson DM, Biedenbach DJ, Beach ML, et al. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37 (2): 99-105
7. Karlowsky JA, Jones ME, Draghi DC, et al. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002 Jan; 42 (1): 59-64
8. Soriano F, Granizo JJ, Fenoll A, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003 Apr; 15 (2): 107-12
9. Jones RN, Biedenbach DJ, Croco MAT, et al. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573-8
10. Fuchs PC, Barry AL, Brown SD. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria. Diagn Microbiol Infect Dis 2000; 37: 265-9
11. Dubois J, St-Pierre C. Superior inhibitory and bactericidal activity of cefditoren against respiratory tract pathogens [poster no. 370]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
12. Ednie LM, Pankuch GA, Jacobs MR, et al. Activity of cefditoren compared with other agents against quinolone and macrolide susceptible and resistant pneumococci [poster no. 378]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
13. Beyer J, Shortridge V, Flamm R, et al. In vitro activity of cefditoren against clinical isolates of S. pneumoniae, H. influenzae, and M. Catarrhalis [poster no. 376]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
14. Peric M, Browne FA, Jacobs MR, et al. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther 2003 Jan; 25 (1): 169-77
15. Clark CL, Nagai K, Dewasse BE, et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002 Jul; 50 (1): 33-41
16. Seki H, Kasahara Y, Ohta K, et al. Antimicrobial activities of cefditoren against respiratory pathogens isolated from children in Japan. J Infect Chemother 1999 Mar; 5 (1): 16-20
17. Sahm DF, Draghi D, Blosser RS, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of non-pneumococcal streptococci collected throughout the United States [poster no. 375]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
18. Granizo JJ, Fernandez-Roblas R, Coronel P, et al. In vitro susceptibility of 590 isolates of S. pyogenes against cefditoren and 10 other antimicrobials: a multicenter international study in Southern Europe (ARISE Project) [abstract no. P1368]. Clin Microbiol Infect 2002 Apr; 8 Suppl. 1: 320
19. Soriano F, Granizo JJ, Coronel P, et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries: the ARISE project. Int J Antimicrob Agents 2004 Mar; 23 (3): 296-9
20. Nishi J, Yoshinaga M, Tokuda K, et al. Oral antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates from Japanese children. Int J Antimicrob Agents 2002; 20: 130-5
21. Sahm DF, Karlowsky JA, Draghi D, et al. Comparative activities of cefditoren and other antimicrobials against recent clinical isolates of H. influenzae and M. catarrhalis collected throughout the United States [poster no. 369]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
22. Karlowsky JA, Critchley IA, Draghi DC, et al. Activity of cefditoren against β-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 2002 Jan; 42 (1): 53-8
23. Balbisi EA. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy 2002 Oct; 22 (10): 1278-93
24. Medeiros AA. Comparison of oral cephalosporins and their activity against β-lactamase-producing bacteria. Infect Dis Clin Pract 1998 Nov; 7 Suppl. 4: S273-9
25. Jones RN, Pfaller MA, Jacobs MR, et al. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis 2001; 41 (1-2): 1-14
26. Spangler SK, Jacobs MR, Appelbaum PC. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other β-lactams. J Antimicrob Chemother 1997; 39: 141-8
27. Dubois J, St-Pierre C. In vitro study of the post-antibiotic effect and the bactericidal activity of cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens. Diagn Microbiol Infect Dis 2000; 37: 187-93
28. Felmingham D, Robbins MJ, Ghosh G, et al. An in vitro characterization of cefditoren, a new oral cephalosporin. Drugs Exp Clin Res 1994; 20: 127-47
29. Draghi D, Selman LJ, Karlowsky JA, et al. Bactericidal activity of cefditoren and comparator agents against penicillin-susceptible, -intermediate, and -resistant isolates of Streptococcus pneumoniae [poster no. 373]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
30. Soriano F, Coronel P, Gimeno M, et al. Inoculum effect and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis. Eur J Clin Microbiol Infect Dis 1996; 15: 761-3
31. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41 Suppl. D: 25-41
32. Ehrhardt AF, Moland ES, Sanders CC. Impact of specific β-lactamase and β-lactamase/porin combinations on the in vitro activity of cefditoren in a genetically defined panel [poster no. 374]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
33. Hasegawa K, Yamamoto K, Chiba N, et al. Diversity of ampicillin- resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist 2003 Spring; 9 (1): 39-46
34. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39 Suppl. A: 1-6
35. Dessen A, Di Guilmi AM, Vernet T, et al. Molecular mechanisms of antibiotic resistance in gram-positive pathogens. Curr Drug Targets Infect Disord 2001; 1 (1): 63-77
36. Nagai K, Davies TA, Jacobs MR, et al. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 2002 May; 46 (5): 1273-80
37. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96
38. Craig WA, Andes DR. In vivo pharmacodynamic activity of cefditoren (CDTR) against Streptococcus pneumoniae [abstract no. 2248]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago
39. Tawara S, Hatano K, Wakai Y, et al. In vivo antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo) 1999; 52 (7): 660-5
40. Sakagami K, Atsumi K, Tamura A, et al. Synthesis and oral activity of ME1207, a new orally active cephalosporin [letter]. J Antibiot (Tokyo) 1990; 43 (8): 1047-50
41. Li JT, Hou F, Lu H, et al. Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 1997; 23: 145-50
42. Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren [poster no. 310]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
43. Mulford D, Mayer M, Witt G. Effect of renal impairment on the pharmacokinetics of cefditoren [poster no. 311]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
44. Mayer M, Mulford D, Witt G. Effect of hepatic impairment on the pharmacokinetics of cefditoren [poster no. 312]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
45. Mayer M, Mulford D, Witt G. Pharmacokinetics of cefditoren in blister fluid and plasma [abstract no. 656]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 20
46. 2 receptor antagonist or an antacid on the pharmacokinetics of cefditoren [poster no. 313]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
47. Mulford D, Mayer M, Witt G. Effect of cefditoren on the pharmacokinetics of ethinyl estradiol [abstract no. 314 plus poster]. 40th Interscience Conference on Antimicrobials Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 13
48. Kinzig-Schippers M, Hinder M, Göhler K, et al. Tissue penetration of cefditoren (CEE) into bronchial mucosa (BM) and epithelial lining fluid (ELF) in patients undergoing fiberoptic bronchoscopy [abstract no. 946]. 41st Interscience Conference on Antimicrobials Agents and Chemotherapy; 2001 Dec 16-19; Chicago, 24
49. Guay DR. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001 Dec; 23 (12): 1924-37
50. Henry DC, Poling TL, Bettis RB, et al. A double-blind, randomized study of cefditoren vs cefuroxime for AECB. J Respir Dis 2001; 22 (8 Suppl.): S69-74
51. Tucker R, Rhudy J, Hunt B, et al. Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis (AECB) [abstract no. 836 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 495
52. Tedec-Meiji Farma S.A. Efficacy of cefditoren-pivoxil compared to cefuroxime-axetil in patients with acute exacerbation of chronic bronchitis in adults. Tedec-Meiji Farma S.A., 2001 (Data on file)
53. Fogarty CM, Cyganowski M, Palo WA, et al. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002 Nov; 24 (11): 1854-70
54. van Zyl L, le Roux JG, LaFata JA, et al. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. Clin Ther 2002 Nov; 24 (11): 1840-53
55. Comparative safety and efficacy of cefditoren pivoxil and Augmentin® (amoxicillin/clavulanate potassium) in the treatment of patients with acute maxillary sinusitis. TAP Holdings Inc., 1999 (Data on file)
56. Multicentre, prospective, comparative, phase III study of cefditoren-pivoxil (CDTR-PI) versus cefuroxime-axetil in the treatment of acute community-acquired sinusitis (ACAS) in adults. Tedec-Meiji Farma S.A., 2001 (Data on file)
57. Gooch W, Marsh D, Stickler T, et al. Cefditoren is safe and effective treatment for streptococcal pharyngitis [abstract no. 837 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 495
58. Multicentre phase III, randomised, comparative study: cefditoren pivoxil (ME1207) with penicillin V in the treatment of acute bacterial pharyngotonsillitis in adults. Tedec-Meiji Farma S.A., 2001 (Data on file)
59. Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg bid with either cefuroxime 250 mg bid or cefadroxil 500 mg bid for the treatment of uncomplicated skin and skin-structure infections. Clin Ther 2002; 24 (7): 1134-47
60. Chow J, Russell M, Volk S, et al. Efficacy of cefditoren pivoxil (CDTR) vs amoxicillin/clavulanate (AMX/CLV) in acute maxillary sinusitis (AMS) [abstract no. 835]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 495
61. Brass EP. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 2002; 54 (4): 589-98
62. Brass EP, Mayer MD, Mulford DJ, et al. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Clin Pharmacol Ther 2003 Apr; 73 (4): 338-47
63. Donowitz GR, Mandell GL. Cephalosporins. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 246-57
64. Perry CM, Scott LJ. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections. Drugs 2004; 64 (13): 1433-64
65. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000 May 22; 160 (10): 1399-408
66. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003 Aug; 52 (2): 229-46
67. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001 Jun; 163 (7): 1730-54
68. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004 Jan; 130 (1 Suppl.): 1-45
69. Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can Respir J 2003; 10 (5): 248-58
70. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001 Dec; 56 Suppl. IV: 1-64
71. Bisno AL, Gerber MA, Gwaltney JMJr, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis: Infectious Diseases Society of America. Clin Infect Dis 2002 Jul 15; 35 (2): 113-25
72. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003 Dec 1; 37 (11): 1405-33